European Medicines Agency (EMA) recommends non-renewal of authorisation of multiple myeloma medicine Blenrep

15 settembre 2023 – EMA’s human medicines committee has recommended not renewing the conditional marketing authorisation for Blenrep (belantamab mafodotin), a medicine used to treat multiple myeloma (a cancer of the bone marrow). Blenrep is given to adults who have received at least four previous treatments and whose disease does not respond to certain other types of cancer treatment, and whose cancer has worsened since receiving the last treatment.

For more information, see here.